Van Andel Institute and Cure Parkinson's Renew $1.5M Annual Funding for World's Largest Parkinson's Drug Repurposing Initiative
核心洞察
Van Andel Institute (搜索) and Cure Parkinson's (搜索) have renewed their three-year funding partnership, pledging $750,000 annually each to support the International Linked Clinical Trials Program (搜索).
The program represents the world's largest drug repurposing clinical trial initiative for Parkinson's disease, having launched 47 trials with over 6,800 participants to date.
Approximately 40% of drugs currently being researched as disease-modifying treatments for Parkinson's have been prioritized by this program's Scientific Committee.
Van Andel Institute (搜索) (VAI) and Cure Parkinson's (搜索) have renewed their funding agreement to support the International Linked Clinical Trials Program (搜索), described as the world's largest drug repurposing clinical trial initiative for Parkinson's disease. The three-year partnership will provide between $1.5 million and $1.75 million annually for disease-modifying Parkinson's research.
Under the renewed agreement, each organization pledges $750,000 annually to the program, with both parties also committing to collaborative fundraising efforts to further support Parkinson's clinical trials. This partnership extends a successful collaboration that began in 2014.
Global Impact on Parkinson's Research
The International Linked Clinical Trials Program (搜索) addresses a critical unmet medical need in Parkinson's disease treatment. An estimated 10 million people worldwide have Parkinson's disease, a number expected to grow as the population ages. While treatments exist to manage symptoms, there are currently no approved therapies to slow or stop disease progression.
"Together with Cure Parkinson's (搜索), we are thrilled to reaffirm our longstanding support of the International Linked Clinical Trials Program (搜索)," said Darren Moore, Ph.D., the Jay Van Andel Endowed Chair in Parkinson's Disease Research at VAI and member of the International Linked Clinical Trials Scientific Committee. "Our renewed agreement will enable the program to continue seeking promising new therapies, with the goal of identifying much-needed ways to impede disease progression and improve quality of life."
Drug Repurposing Strategy
The program's innovative approach focuses on evaluating potentially disease-modifying treatments through drug repurposing. Many medications included in the trials were originally designed or approved to treat other diseases, an approach that can save significant time and resources since candidate medications have already cleared rigorous safety and efficacy testing.
Medications are reviewed and prioritized by the program's Scientific Committee, which comprises Parkinson's researchers, medical professionals and advocates. The program's influence on the field is substantial, with approximately 40% of drugs currently being researched as disease-modifying treatments for Parkinson's having been prioritized for clinical trials by the International Linked Clinical Trials Program (搜索).
Trial Portfolio and Participation
Since the program's inception, it has demonstrated significant reach and impact. More than 6,800 people with Parkinson's have participated in International Linked Clinical Trials-associated trials. Of the 47 trials launched by the program, 19 are currently ongoing and 28 have been completed. VAI funds have specifically supported 10 of these trials.
"This new matched funding agreement makes between $1,500,000 and $1,750,000 available each year for disease-modifying Parkinson's research," said Helen Matthews, CEO of Cure Parkinson's (搜索). "The funding will support clinical trials and related projects as part of the International Linked Clinical Trials initiative, our thriving global program that aims to develop new treatments to slow, stop or reverse Parkinson's."
The renewed partnership underscores the continued commitment of both organizations to advancing Parkinson's research and their shared goal of identifying effective disease-modifying therapies for the millions of people affected by this progressive neurological condition.